4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
VYNE Therapeutics Inc. (VYNE) operates in the Biotechnology industry and is headquartered in Stewartsville, United States with about 10 employees. Its market capitalization is roughly $22 million. In the fiscal year ended 2025-12-31, VYNE reported $1M in revenue and ($26M) in net income.
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions.
Interactive charts & full statements → Open the VYNE valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $1M | $0M | $0M | $0M | — |
| Gross Profit | — | — | — | — | $11M |
| Operating Income (EBIT) | ($30M) | ($44M) | ($29M) | ($34M) | — |
| Net Income | ($26M) | ($40M) | ($28M) | ($23M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($4M) | ($5M) | ($8M) | ($8M) | ($9M) | — |
| Net Income | ($4M) | ($5M) | ($7M) | ($6M) | ($9M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $30M | $67M | $98M | $41M | — |
| Total Liabilities | $2M | $15M | $9M | $10M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VYNE viewer.
About TickerBase · Data methodology & sources